IP Library › Granted Patent US 12,404,333
Granted Patent B2
US 12,404,333 · App. 17/312,884 · Granted Sep 2, 2025

Anti PD-L1 antibody and use thereof

Inventors: Jianmin Fang (Shandong, CN); Jing Jiang (Shandong, CN); Shenjun Li (Shandong, CN); Guorui Zhao (Shandong, CN)
Assignee: REMEGEN CO., LTD.
C07K16/2827A61P35/00A61K2039/505C07K2317/24C07K2317/76C07K2317/92C12N15/62C12N15/63C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,333
App. No.
17/312,884
Granted
Sep 2, 2025
Kind
B2
Abstract

Provided in the present invention is a PD-L1 immunosuppressant, and specifically provided are a monoclonal antibody capable of targeting PD-L1, and nucleotides, combinations of polynucleotides, expression vectors and combinations of expression vectors encoding the antibody. Also provided in the present invention is a conjugate or pharmaceutical composition containing the above-mentioned anti PD-L1 antibody. Further provided in the present invention is the use of the above-mentioned anti PD-L1 antibody, nucleotides, combinations of polynucleotides, expression vectors, combinations of expression vectors, conjugate or pharmaceutical composition in the preparation of a medicament for treating or preventing cancers.

Claims (23)

1. An isolated anti-PD-L1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise the following CDRs:

(1) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 1-3 respectively, and the CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 4-6 respectively; or

(2) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 7-9 respectively, and CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 10-12 respectively; or

(3) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 13-15 respectively, and CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 16-18 respectively; or

(4) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 19-21 respectively, and CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 22-24 respectively; or

(5) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 25-27 respectively, and CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 28-30 respectively.

2. The antibody or antigen-binding fragment thereof according to claim 1 , wherein:

(1) the heavy chain variable region comprises the same CDRs 1-3 as in SEQ ID NO: 31 and are more than 95% identical to SEQ ID NO: 31; and

(2) the light chain variable region comprises the same CDRs 1-3 as in SEQ ID NO: 32 and are more than 95% identical to SEQ ID NO: 32.

3. The antibody or antigen-binding fragment thereof according to claim 1 , wherein:

(1) the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 31; and

(2) the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 32.

4. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody is a monoclonal antibody, chimeric antibody, humanized antibody, bispecific antibody, multispecific antibody or Fab Fragment, F(ab′) fragment, F(ab′) 2 fragment, Fv fragment, dAb, Fd, or single chain antibody (scFv).

5. An isolated polynucleotide encoding the antibody or antigen-binding fragment thereof according to claim 1 .

6. A combination of an isolated polynucleotide encoding the heavy chain of the antibody or antigen-binding fragment thereof according to claim 1 and an isolated polynucleotide encoding the light chain of the antibody or antigen-binding fragment thereof according to claim 1 .

7. A nucleic acid construct comprising the polynucleotide according to claim 5 .

8. A host cell comprising the nucleic acid construct of claim 7 .

9. An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof according to claim 1 and a drug toxin.

10. A composition comprising the antibody or antigen-binding fragment thereof according to claim 1 , and a pharmaceutically acceptable carrier.

11. A method for the manufacture of an anti-PD-L1 antibody, comprising culturing the host cell according to claim 8 under a condition suitable for a vector encoding the anti-PD-L1 antibody or antigen-binding fragment to be expressed, and recovering the antibody or fragment.

12. The antibody or antigen-binding fragment thereof according to claim 1 , wherein:

(1) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO: 33; and

(2) the light chain comprises the amino acid sequence as shown in SEQ ID NO: 34.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2021
From: FANG, JIANMIN; JIANG, JING; LI, SHENJUN; ZHAO, GUORUI
To: REMEGEN CO., LTD.
Reel/Frame 056511/0176 →
Priority Claims (1)
CN 201910805440.7 · Aug 29, 2019 · national
Continuity (1)
Related Publication 20220177590A1 · Jun 9, 2022
References Cited (48)
US 9334331B2 · Igawa · 2016 [cited by examiner]
US 10421807B2 · Gonzales · 2019 [cited by examiner]
US 20190083644A1 · Yoo et al. · 2019 [cited by applicant]
CA 3137211A1 · 2021 [cited by applicant]
CN 104470949A · 2015 [cited by applicant]
CN 109195991A · 2019 [cited by applicant]
CN 109232740A · 2019 [cited by applicant]
CN 109627338A · 2019 [cited by applicant]
EP 3378871A1 · 2018 [cited by applicant]
EP 3470429A1 · 2019 [cited by applicant]
EP 3858862A1 · 2021 [cited by applicant]
JP 2018536401A · 2018 [cited by applicant]
RU 2523894C2 · 2014 [cited by applicant]
RU 2580045C2 · 2016 [cited by applicant]
TW 201620936A · 2016 [cited by applicant]
WO WO2007005874A2 · 2007 [cited by applicant]
WO WO2017020858A1 · 2017 [cited by applicant]
WO WO2017058859A1 · 2017 [cited by applicant]
WO WO2017132562A1 · 2017 [cited by applicant]
WO WO2017220990A1 · 2017 [cited by applicant]
WO WO2018052818A1 · 2018 [cited by applicant]
WO WO2019129211A1 · 2019 [cited by applicant]
Al Qaraghuli et al. (2020, Nature Scientific Reports 10:13969). [cited by examiner]
Edwards et al. (2003, JMB 334:103-118). [cited by examiner]
Lloyd et al. (2009, Protein Engineering, Eng. Design & Selection 22(3): 159-168). [cited by examiner]
Goel et al. (2004, J. Immunol. 173: 7358-7367). [cited by examiner]
Khan et al. (2014, J. Immunol. 192: 5398-5405). [cited by examiner]
Poosarla et al. (2017, Biotechn. Bioeng. 114(6): 1331 -1342). [cited by examiner]
Rabia et al. (2018, Biochemical Engineering Journal 137:365-374). [cited by examiner]
Gura (Science, v278, 1997, pp. 1041-1042). [cited by examiner]
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4). [cited by examiner]
Zips et al. (2005, In Vivo 19:1-8). [cited by examiner]
Editorial, (2013, Nature Biotechnology 31:85). [cited by examiner]
International Search Report in PCT/CN2020/110935 mailed Dec. 2, 2020. [cited by applicant]
Chen, L and Flies, D B., “Molecular mechanisms of T cell co-stimulation and co-inhibition”, Nature Reviews Immunology, 2013, 13(4): 227-242. [cited by applicant]
Ohaegbulam, K C et al., “Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway,” Trends in Molecular Medicine, 2015, 21(1): 24-33. [cited by applicant]
Ishida, M et al., “Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues,” Immunology Letters, 2002, 84(1): 57-62. [cited by applicant]
Taube, J M et al., “Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape”, Science Translational Medicine, 2012, 4(127): 1… [cited by applicant]
Tseng, S Y et al., “B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells,” The Journal of Experimental Medicine, 2001, 193(7): 839-845. [cited by applicant]
Butte, M J et al., “Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses,” Immunity, 2007, 27(1): 111-122. [cited by applicant]
Cheng X et al., “Structure and interactions of the human programmed cell death 1 receptor,” The Journal of Biological Chemistry, 2013, 288(17): 11771-11785. [cited by applicant]
Dirix, Luc Y., “Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor Study”, Breast Cancer Res Treat (2018) 167:671-686. [cited by applicant]
Boyerinas, Benjamin, et al., “Antibody-dependent cellular cytotoxicity (ADCC) activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells,” Cancer Immunol Res. Oct. 2015; 3(10): 1148-1157. [cited by applicant]
Liu, An, “Discovery on small molecular inhibitors of PD-1/PD-L1 pathway”, Jilin: Jilin University School of Pharmaceutical Sciences, 2016, (in 77 pages). [cited by applicant]
European Search Report received in European Application No. 20859087.7 dated Jun. 13, 2022 in 9 pages. [cited by applicant]
Japanese Office Action received in Japanese Application No. 2021-549665 dated Aug. 18, 2022 in 14 pages. [cited by applicant]
Russian Office Action in Russian Patent Application No. 2021108266 issued Jan. 21, 2022. [cited by applicant]
Pakula, Andrew A., et al., “Genetic Analysis of Protein Stability and Function,” Annual Rev. Genet. 1989, 23:289-310. [cited by applicant]